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Abstract
The	history	of	pediatric	allergology	(PA)	in	Europe	is	relatively	youthful,	dating	back	to	
1984,	when	a	small	group	of	pediatricians	founded	the	European	Working	Group	on	
Pediatric Allergy and Immunology—later giving rise to ESPACI (European Society on 
Pediatric Allergology and Clinical Immunology). In 1990, the first dedicated journal, 
Pediatric	Allergy	and	Immunology	(PAI),	was	founded.	There	are	striking	differences	
across Europe, and even within European countries, in relation to the training path-
ways for doctors seeing children with allergic disease(s). In 2016, the EAACIClemens 
von	Pirquet	Foundation	(CvP)	organized	and	sponsored	a	workshop	with	the	European	
Academy of Allergy and Clinical Immunology (EAACI) Pediatric Section. This collabora-
tion	focussed	on	the	future	of	PA	and	specifically	on	education,	research,	and	network-
ing/ advocacy. The delegates representing many countries across Europe have 
endorsed the concept that optimal care of children with allergic diseases is delivered 
by pediatricians who have received dedicated training in allergy, or allergists who have 
received dedicated training in pediatrics. In order to meet the needs of children and 
families with allergic disease(s), the pediatric allergist is highly encouraged to develop 
several	networks.	Our	challenge	is	to	reinforce	a	clear	strategic	approach	to	scientific	
excellence to across our member base and to ensure and enhance the relevance of 
European pediatric research in allergy. With research opportunities in basic, transla-
tional, clinical, and epidemiologic trials, more trainees and trained specialists are 
needed and it is an exciting time to be a pediatric allergologist.
K E Y W O R D S
allergy, anaphylaxis, asthma, children, drug, food allergy, pediatric allergology, pediatrics, training, 
trial
1  | INTRODUCTION
The history of pediatric allergology (PA) is relatively youthful: in 1984 
in Europe, a small group of pediatricians founded the first European 
Working	Group	on	Pediatric	Allergy	and	Immunology—later	giving	or-
igin to ESPACI (European Society of Pediatric Allergology and Clinical 
Immunology).1 ESPACI was a response to the need for a subgroup 
within the allergy community focusing on the specific unmet needs 
of infants and children developing atopic disease manifestations. Until 
that	time,	infants	and	children	with,	or	at	risk	of	atopic	dermatitis,	food	
allergy, asthma, allergic rhinitis, and/or drug allergy had only the choice 
of	a	general	pediatrician,	a	specialist	with	a	strong	background	in	adult	
allergy or a specialist with a special interest but no formal training in 
allergy. The absence of a holistic, family- focused approach to aller-
gic conditions may have resulted in significant additional burden with 
respect to the prevalence and morbidity of atopic diseases in the first 
years of life.
In the subsequent years, global interest in pediatric allergy re-
search, be it basic, translational, and/or clinical, grew and so did the 
focus on research quality. Simultaneously, sessions on pediatric allergy 
at international conferences increased in popularity. In 1990, a dedi-
cated journal, Pediatric Allergy and Immunology (PAI), was founded. 
Now most conferences include a considerable number of pediatric 
sessions.
A	patchwork	of	differential	recognition	for	the	discipline	of	PA	de-
veloped in Europe in accordance with the fact that in some countries, 
allergology is recognized as a full specialty, while in others it is seen 
as a subspecialty within, for example, dermatology, ENT, respiratory 
medicine and pediatrics. Early attempts to harmonize the structure 
of patient care in this area across Europe were unsuccessful until 
     |  11TSILOCHRISTOU eT aL.
the European Academy of Pediatrics (EAP) officially accepted PA as a 
	certified	and	acknowledged	subspeciality	in	1999.
The EAACI- Clemens von Pirquet Foundation (CvP) is a non- profit 
foundation established to promote research and education in pediatric 
allergy. In a sponsored collaboration with the European Academy of 
Allergy and Clinical Immunology (EAACI) Pediatric Section, CvP orga-
nized	in	Rome,	October	2016,	a	workshop	on	the	future	of	PA,	with	
a	deliberate	focus	on	education,	research,	and	networking/advocacy.	
Invited delegates were the members of the CvP board and senior and 
junior representatives from EAACI Sections and Interest Groups re-
lated to the focus topic. These delegates represented many countries 
across Europe and CvP additionally invited other representative pe-
diatric allergists. Valuable insights were requested from two experts 
with	backgrounds	in	pediatric	drug	development,	 including	immuno-
therapy. The authors of this paper were all active participants of this 
workshop.	The	paper	represents	an	official	statement	of	CvP	and	the	
EAACI Section on Pediatrics.
2  | STATUS QUO IN PEDIATRIC 
ALLERGOLOGY IN EUROPE
More than two decades after the EAP officially accepted PA as a cer-
tified	and	acknowledged	subspecialty	within	pediatrics,	there	are	still	
striking	differences	across	Europe	in	the	training	pathways	for	doctors	
seeing children with allergic disease(s). The types of doctors currently 
engaged in PA in Europe can be outlined as followed:
1. Those fully trained in general pediatrics with (extra) dedicated 
time in allergy. These are pediatricians who have a special 
interest in allergy, and the allergy-dedicated training duration 
varies	among	countries,	 for	example,	 in	UK	where	this	 is	known	
as SPIN (special interest) in allergy and tends to be for those 
who	 wish	 to	 work	 in	 secondary	 service	 with	 dedicated	 allergy	
clinics.
2. Those trained where PA is a subspecialty within pediatrics, 
namely through an (integrated) general pediatrics (core) training 
and full specialist allergy training program leading to accredita-
tion as pediatric allergists. In these countries, PA is regarded as a 
full	 (sub)specialty,	 for	example,	Sweden,	Turkey,	Denmark,	and	
UK. Subspecialty pediatric allergy training in the UK is a 3-year 
program approved by the Royal College of Paediatrics and Child 
Health, and subspecialty accreditation is awarded by the General 
Medical	Council;	this	is	the	usual	route	to	working	in	a	tertiary	or	
academic	 UK	 allergy	 unit.	 In	 Turkey,	 after	 5	years	 of	 general	
pediatric specialty, the pediatric immunology and allergy training 
are independent 3-year full specialty program. Of note, in some 
countries, pediatricians that have been dedicated to seeing al-
lergic children for a specified sufficient period of time have been 
granted accreditation as pediatric allergists (such as in Spain with 
pediatricians consulting allergic children for 5 years or more).
3. Those who have completed core training in adult general medicine 
and, in some cases, a short or equal period of pediatrics, followed 
by a combined clinical training in child and adult allergy. These are 
allergists and allergy is considered as a full (sub)specialty. 
Representative examples of countries implementing this training 
system are Greece, Portugal, Spain, France, and Romania.
4. A fourth setting exists where allergy is not regarded as specialty, 
and the onus is on the individual physician to train themselves to 
feel confident in seeing children with allergic problems. This may 
happen in the case of adult ENT and ophthalmology surgery spe-
cialists	 in	 Germany,	 for	 example,	 and	 the	Workshop	 agreed	 this	
situation is suboptimal for both the patients and the physicians in-
volved. This setting includes many clinicians appointed to posts in 
the 1990s and 2000s.
It	 is	 also	vital	 to	 acknowledge	 and	 consider	 the	 experienced	 non-	
medical healthcare professionals (HCP) who support and add value to 
the optimal diagnosis and management of allergy in children. Countries 
differ in the training and utilization of allied HCP within the allergy teams. 
Specialist nursing and dietetic clinics already occur in some allergy centers 
in the UK and Scandinavia.2 However, to date, the authors are unaware 
of an accredited curriculum and certification in allergy in Allied Health, al-
though ratified 2- year training programs for asthma or eczema exist. This 
issue	could	and	should	be	addressed	with	the	appropriate	stakeholders.
All	 delegates	 of	 the	workshop	 have	 endorsed	 the	 concept	 that	
optimal care of children with allergic diseases is delivered by pedia-
tricians who have received dedicated training in allergy, or allergists 
who have received dedicated training in pediatrics. Therefore, the pro-
posed way forward is for only these specialists to be accredited to 
consult children with allergic diseases in the near future. Nonetheless, 
the	panel	acknowledges	the	idiosyncrasies	of	each	country’s	specialty	
training programs. Respect is given to the fact that there are allergists 
with	general	adult	medicine	as	their	background	who	have	been	see-
ing allergic children routinely, especially in light of the absence of pe-
diatric allergists in their country. On this basis and for the time being, 
doctors currently engaged in PA who have not undergone pediatric 
training	but	can	demonstrate	 the	necessary	skills	and	competencies	
can still be considered to be accredited as pediatric allergologists, 
akin	 to	 the	 ‘grandfather’	 clause	 that	 allows	 continuing	 practice	 for	
those appointed/in post before formal accreditation processes were 
established.	 In	 countries	where	PA	 is	 an	 acknowledged	 specialty	 or	
where	there	are	EAP-	certified	PA	centers,	accreditation	can	take	place	
through a formal application of the doctor to the PA national society 
or PA center of the country, respectively. The role of the ETC- PA in 
individual certification of European Specialists and center certification 
has	been	a	key	to	the	development	of	PA	in	Europe.	Although	not	a	
legal license to practice, this certification is an important asset to an in-
dividual CV, particularly in countries where PA does not officially exist 
and may also help to give visibility to the subspeciality and to influence 
its recognition. It is also a prerequisite to accredit training centers, as 
teachers must be qualified and recognized as such. After international 
visitation and accreditation, all involved centers to date (6 in Spain 
and 7 in Sweden) agreed that this initiative led to an improvement in 
teaching quality, clinical quality, planning of training, and training of 
techniques.
12  |     TSILOCHRISTOU eT aL.
Notably,	it	is	up	to	national	bodies	to	acknowledge	subspecialties	
and to define the rules for training center accreditation and subspe-
cialist certification in their countries. These rules should ideally be 
similar all over Europe. In countries where a given subspecialty is not 
recognized, the international certification of centers may play a crucial 
role in promoting the visibility and final recognition of this field as a 
specialized area of medicine in that country.
3  | EDUCATION ACCORDING TO THE EAP 
EUROPEAN PAEDIATRIC ALLERGOLOGY 
TRAINING PROGRAMME
The European Paediatric Allergology Training Programme was firstly 
approved in 1999 and revisions made until a consensus syllabus was 
approved in the end of 2016.3 It is one of the subspecialist training 
programs in tertiary care pediatrics, defined by the Tertiary Care 
Group of EAP, itself the Paediatric section of the European Union of 
Medical Specialists (Union Européenne des Médecins Spécialistes—
UEMS). Based on this program, pediatric allergists are expected to 
practice	 their	 skills	 and	 apply	 their	 expertise	within	 the	 framework	
of a specialized tertiary care unit. These specialists will also have the 
commitment of training general pediatricians and pediatricians with 
interest in PA.
According to this training program, all doctors practicing PA re-
quire a prescribed and nationally accredited basic training in general 
pediatrics, as set out by many National Training Authorities, and the 
recommended	 European	 Common	 Trunk	 Syllabus,	 approved	 by	 the	
EAP- UEMS. This program stipulates 3 years minimum in general pedi-
atrics, serving as a prelude to PA. In some countries, a clinical training 
period of 24- month full- time employment in PA is considered ade-
quate, but others require longer for accreditation.
Nevertheless, the content or competencies demonstrated and 
not the length of education a priori should be the basis of PA sub-
specialty certification. A precise training syllabus3 is detailed in the 
European Pediatric Allergology Training Programme. This is structured 
in modules, each containing training requirements in a specific area, 
expertise,	 or	 skill.	 Simultaneous	 training	 in	 several	 modules	 is	 pos-
sible, according to local service and training configurations. Training 
can be completed with modules acquired in several different training 
centers, with at least one named, trainer- recognized primary center. 
Immunology is regarded as an add- on module and in some countries a 
separate subspecialty. Immunodeficiencies are not officially included 
in the PA curriculum.
Competency-	based	assessment,	as	an	adjunct	to	knowledge	as-
sessment and portfolio completion, is an important aspect of eval-
uation. Several countries have recently reformed their postgraduate 
medical education, and competencies should be evaluated through-
out the training period. PA trainees are encouraged and required to 
keep	a	contemporaneous	written	logbook	of	patients	they	have	seen,	
together with procedures conducted, and the therapeutic interven-
tions instigated and followed up. This will constitute part of their 
portfolio.
Research training is considered an essential aspect of the PA cur-
riculum. Furthermore, attendance at International Congresses and giv-
ing 2 to 3 presentations in such meetings are highly recommended.
4  | PEDIATRIC ALLERGY EXAMS
A	knowledge-	based	assessment	is	desirable	and	preferably	included	
in a national final examination. EAACI is currently organizing a 
modification of the EAACI Knowledge Exam which offers an official 
knowledge	certificate	for	allergists/clinical	immunologists.	This	modi-
fication will lead to a specific certification for pediatric allergists on 
a European and global level. This will impact on the implementation 
of structured pediatric allergy care in all European countries. In addi-
tion,	it	could	offer	an	optional	replacement	for	the	knowledge-	based	
assessment of PA national certification, provided it is accepted by 
the relevant national authority. These EAACI Exams on PA are antici-
pated to help the harmonization of education and exchange of young 
doctors	in	the	PA	field	across	Europe.	Moreover,	this	kind	of	certifi-
cate will be of value for national validation. While the examination 
may not replace the established training and rules for the specialty 
foreseen	by	each	nation,	this	kind	of	certificate	will	be	of	value	as	an	
additional qualification.
5  | NETWORKS FOR PEDIATRIC 
ALLERGISTS ACROSS EUROPE
In order to meet the needs of children and families with allergic 
disease(s), the pediatric allergist is highly encouraged to develop sev-
eral	 networks	 (Figure	1).	 Engaging	 with	 different	 groups	 facilitates	
education, training, clear communication, creates the opportunity to 
develop shared pathways for patients, as well as for recruiting poten-
tial experts in the field.
5.1 | Multidisciplinary team pediatric allergy clinics
Pediatric subspecialty services are becoming increasingly multidis-
ciplinary. Proposed members of the allergy multidisciplinary team 
(MDT) include pediatric allergists, specialist nurses, dietitians, and 
psychologists.	The	ideal	is	to	have	a	“one-	stop	shop”	model	where	
children and their families attend pediatric allergy clinics composed 
of	MDT	members.	The	skillset	of	the	MDT	is	diverse	and	may	over-
lap. Generally: medical clinicians have overarching responsibility 
for patients; dietitians guide exclusion diets and reintroductions 
as well a facilitate optimal nutrition; and nurses usually support 
food and drug challenges, perform allergy tests, as well as ensure 
emergency plans are in place. In addition, nurses most often liaise 
with schools in order to ensure the child is safe in the community—
this can involve visiting schools or training school nurses to rec-
ognize and treat allergic reactions. The roles of MDT members are 
expanding; many centers are developing nurse- led and dietetic- 
led clinics where clinically appropriate, which increases access 
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for patients. This creates opportunities for focused and practical 
education	and	quality-	of-	life	 improvements.	The	“one-	stop	shop”	
model	makes	holistic	patient	care	more	efficient.	MDTs	could	be	
even broader and include liaison with allergy- related pediatric 
subspecialties, such as ENT, respiratory, gastroenterology, derma-
tology, and ophthalmology teams. There are centers which have 
set up joint clinics where patients are assessed by subspecialists 
simultaneously—the provision of this service mostly depends on 
local resources.
5.2 | Primary care
In many European countries, the majority of patients with allergic 
disease(s) will consult first with their primary caregiver (eg, general 
practitioner [GP] in the UK, general pediatrician in Switzerland). 
Remarkably,	 one-	third	 of	 all	 UK	 GP	 consultations	 in	 2007	 were	
due	 to	 allergic	 diseases.	 Although	 pediatric	 allergy	 networks	 and	
national societies are engaged and annual meetings well attended, 
they	 infrequently	 involve	 the	primary	 caregiver.	 Establishing	 links	
with primary caregivers will create opportunities—for education and 
training, as well as to facilitate prompt referrals and shared care 
for	patients.	Regional	networks	can	be	a	way	of	 involving	primary	
care in continuous education and pediatric allergists must reach out 
to primary care where time for training might be scarce. Other ini-
tiatives include EAACI primary care symposia during EAACI meet-
ings and adaptation of an EAACI masterclass in PA for primary care 
physicians.
5.3 | Regional networks
In	 some	 European	 countries,	 regional	 networks	 are	 increasingly	
popular, as they facilitate education and information dissemination 
among pediatric allergy MDT across the region. Tertiary centers tend 
to coordinate meetings, with attendance from MDT members from 
secondary care hospitals and occasionally by primary care. There is 
an opportunity to collect regional data, for example, for asthma, food 
challenges, and creating regional guidelines, such as standardized 
food challenge, referral pathways for drug allergy, or even to conduct 
audits. Most importantly, there is an opportunity to discuss cases, 
be it simple or complex, among experts from the tertiary center. We 
strongly	support	the	constitution	of	regional	clinical	networks	led	by	
trained and experienced pediatric allergists, and including physicians 
and allied health professionals involved in the care of allergic children 
and	adolescents.	Clinical	and	 research	networks	also	need	 to	 focus	
on strategic partnerships and collaboration with adult colleagues to 
better understand how to support each other’s needs and to align 
activities.
5.4 | International networking
Well- established PA centers can offer great support to centers in other 
countries where PA is emerging. Short, as well as longer term, visits to 
both	sides	of	the	network	should	be	encouraged,	not	only	for	train-
ees, but also for established professionals. Moving to a country with a 
higher	cost	of	living	is	a	major	problem	impairing	the	ability	to	take	up	
F IGURE  1 Networks	for	pediatric	
allergists across Europe [Colour figure can 
be viewed at wileyonlinelibrary.com]
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a training or sabbatical position. Fostering and supporting the activities 
of pediatric allergists in their local centers as well as exchanges across 
clinical	and	research	networks	allow	growth	of	expertise	and	sharing	
of ideas. With this in mind, it has been noted that fellowship grants 
and training opportunities should be available to those who are still 
or have just completed their training but no longer qualify for junior 
membership, for example, at EAACI. Similarly, consultants in post have 
expressed the wish to learn from other centers in a way which realisti-
cally	allows	useful	networking	and	cross-	pollination	of	ideas.
Certification of PA centers for training through ETC- PA should be 
encouraged. Certified centers will be identified as resource centers for 
exchange and will testify to a high level of clinical care. In addition, it 
is	important	to	acknowledge	centers	that	provide	excellent	clinical	or	
research exposure to specific aspects of PA, to avoid oversubscrip-
tion	of	well-	known	centers,	and	to	engage	and	develop	new	centers	
of excellence.
5.5 | Medical students and pediatric trainees
Provision of allergy teaching within the undergraduate curriculum is 
variable throughout Europe. Medical schools might allocate a most 
commonly restricted time for undergraduate allergy teaching. It is vital 
that undergraduate medical students are exposed to the specialty to 
foster the interest and enthusiasm of individuals interest and enthu-
siasm in individuals who may become future specialists in the field. 
Similarly, allergy training should be offered to pediatric trainees in 
order to generate interest and recruitment into PA.
5.6 | Social media and modern communication Apps
Digital tools are useful for communication among healthcare 
professionals	 who	 provide	 pediatric	 allergy	 services.	 In	 Turkey,	
for instance, a closed WhatsApp group was created to facilitate 
case discussions among HCP who deal with children with allergic 
disease(s).
Facebook	 is	 a	 popular	 platform	 for	 patients/families	 to	 interact.	
Similarly, Twitter has been gaining increasing interest the last years in 
the medical community as its users can:
1. follow a Journal’s latest articles (eg, through the hashtag #PAI_
Journal	 for	 all	 PAI	 papers)	 or	 many	 of	 the	 key	 messages	 pre-
sented in Meetings’ sessions (eg, via #EAACI2017 for all twitter 
posts on the EAACI Congress 2017),
2. participate in Twitter discussions meant either for professionals 
(eg, via #AboutAllergy for twitter discussions organized by EAACI) 
or patients and lay public (eg, through #AllergyReady).
These potentially powerful learning and communication tools 
also require some guidance for optimal clinical conduct and gov-
ernance and need to be identifiably distinct and separate from un-
governed	patient/parent	sites	which	are	not	backed	by	science	and	
medical expertise. For all information in the public domain, strict pa-
tient confidentiality has to be adhered to, in accordance with, local 
trust guidelines. EAACI has an annex dedicated to the proper use of 
social media by HCP as part of the EAACI code of ethics.4 In time, 
there	is	likely	to	be	a	need	for	formal	education	on	this	included	as	
part of training.
5.7 | Media
Pediatric allergology is a topic of wide interest to the media. Aside from 
social media, some may find it useful to engage with the traditional 
media of communication in order to ensure seamless dissemination 
of the correct information. Effective and coordinated communica-
tion can avoid negative publicity due to fatalities, near- misses from 
food anaphylaxis, for example, or may be better presented as a result. 
Additionally, effective liaison with and through the media should be 
communicated at national and EU level aiming at promoting the prior-
itization of allergic diseases.
5.8 | Patient organizations
Pediatric allergists engage with and support professional patient or-
ganizations to further support families. This creates an educational 
opportunity—ensuring that scientific information is understood by 
patients and families for better outcomes and that our patients’ needs 
are met and their priorities held paramount.
5.9 | Pharmacists
In	addition	to	their	knowledge	of	medicines,	pharmacists	also	provide	
advice, information, and treatment for a number of chronic conditions 
and play a vital part in health promotion and disease prevention initia-
tives. Pharmacists are educated to support patients manage medicines 
and their side effects effectively5 while they contribute to improved 
patient adherence. Therefore, they are important liaisons for pediatric 
allergists and can further contribute to increased awareness of allergic 
diseases.
6  | CURRENT STATE AND FUTURE OF 
PEDIATRIC ALLERGY RESEARCH IN EUROPE
Recent years have seen significant advances in our understand-
ing	of	allergenic	pathophysiology	and	tolerance	induction.	Work	is	
underway to assess the generalizability and feasibility of practical 
recommendations for optimal public health impact. There are also 
several new therapeutic drug options becoming available which 
need pediatric trials. With research opportunities in basic, trans-
lational, clinical, epidemiologic, and drug trials, more trainees and 
trained specialists are needed. It is certainly an exciting time to be a 
pediatric allergologist!
Our challenge now is to develop a clear strategic approach to sci-
entific excellence to across our member base and to ensure and en-
hance the relevance of European pediatric research in allergy (Table 1). 
Several	key	areas	for	potential	investment	include:
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6.1 | Prevention of allergic disease(s)
Research is ongoing for the prevention of eczema, food or respira-
tory allergy, or required in the epidemiology of allergy; genetics, im-
munology, molecular, and cellular mechanisms of the allergic immune 
response and for drugs suitable for children.
Basic science research is underrepresented in pediatric medicine, 
and this should be strategically highlighted to the EU and national 
funding agencies. Recent studies have made significant inroads into 
understanding the pathophysiology of tolerance induction, as well 
as the specifics of primary food allergy prevention. These messages 
necessarily lead to further epidemiologic and clinical translational 
and intervention studies. Pediatric medicine is a fertile research 
ground for cohort studies but, for reasons not fully explored in the 
remit	of	this	paper,	it	has	been	historically	weak	on	trials	and	this	is	
due to change.
6.2 | Diagnostic tools and management in PA
Better child and young person- centric diagnostic tools are needed to 
avoid misdiagnosis or unnecessary positive challenges. In vitro diag-
nostics appear promising with respect to predicting positive food or 
drug	challenges,	but	there	is	much	work	to	be	done	in	relation	to	eas-
ier and accurate diagnosis of non- IgE allergy. Research in diagnostic 
biomarkers	also	needs	to	take	into	account	if,	and	how,	the	potentially	
different physiology of children is important at different age ranges. 
Accurate	and	earlier	diagnostics	for	allergic	diseases	and	risk	of	devel-
opment would help prevent missing the window of opportunity and 
thus optimize chances of primary and secondary prevention.
At the same time, effective research in drug allergy in children—
and more effective means of navigating difficult and slow processes 
related to drug research in children—is much needed. An example of 
important public health intervention resulting from such research is 
the removal of pholcodine from over the counter products, such as 
children cough syrups. The wide- scale reduction in exposure to this 
allergen means potentially fatal anaphylactic reactions to neuromus-
cular	blocking	drugs	may	be	prevented.
Allergen- specific immunotherapy (AIT), first described in 1908, 
has recently been rejuvenated with respect to oral, epicutaneous, 
sublingual, or subcutaneous modalities for food allergy as well as with 
the introduction of peptides instead of whole extracts against allergic 
rhinitis.6 More child- friendly and better access to AIT is required, as is 
better standardization and training. Ongoing surveillance of adverse 
side effects and tolerability as regards quality of life is imperative.
6.3 | New drug development and trials for pediatric 
safety and efficacy
It	is	known	that	drugs	for	neonates,	infants,	and	very	young	children	
need to be reviewed with respect to drug absorption, distribution, 
metabolism, and excretion and the implication on drug usage, espe-
cially	dose.	However,	for	older	children,	despite	acknowledgment	that	
brain	maturation	may	take	up	to	25	years,	pharmacological	or	meta-
bolic characteristics may be as for adults. Of note though, EU pediatric 
regulation requires a pediatric investigation plan (PIP) for every new 
drug	as	a	condition	for	marketing	approval.
It is important to discuss that AIT products in the EU were exposed 
to	two	key	legislations	in	2007/2008:	a	requirement	for	PIP	submis-
sion, and the German therapy allergen ordinance.7 The latter made it 
mandatory for manufacturers to register every AIT product, despite 
being	 in	 use	 for	 decades.	As	Germany	 is	 the	 largest	market	 for	AIT	
products, this affected all allergen AIT manufacturers in Europe. More 
than a hundred PIPs were submitted in short time, resulting finally in a 
massive study program proposed to involve 58 five- year double- blind 
randomized placebo- controlled allergen AIT safety and efficacy trials 
with several hundred participants. The deadline for these studies is 
December 2031. While aspects of current AIT products on the mar-
ket	need	appropriate	study	and	review,	there	is	concern	that	the	re-
quirement for participation of thousands of children and adolescents 
potentially	leaves	children	at	risk	of	unnecessary	morbidity	and,	those	
assigned	to	placebo	groups,	at	risk	of	progression	or	march	of	allergic	
disease.
Many clinical specialists are unaware of this issue and would 
rationally question the necessity of trials which would hold up the 
ability of children to benefit from medications that have been proven 
to be of benefit in adults. The PIP system is due for discussion in 
the EU parliament, and it is hoped that representatives from PA and 
EAACI will raise their voice together with those from other pediatric 
 specialties8	 to	 review	 the	 EMA’s	 position	 which	 risks	 suffocating	
pharmaceutic innovation.
6.4 | Innovation and technology
Innovation and technology for better personalized clinical care, 
public health, and research tools is a growing and rapidly changing 
field. EAACI is already cognisant of this fact and a mobile health 
taskforce	has	been	created	to	evaluate	and	develop	the	organiza-
tion’s approach. The promise is of more effective tools to monitor 
patients, to educate patients or professionals, and to improve ad-
herence. These potential benefits need to be rigorously evaluated 
to assess the true impact and whether or not the mobile health or 
digital tools are indeed effective in improving education, adher-
ence, and self- efficacy in the management of allergic diseases. 
Collaboration and engagement with primary care and public health 
as well as extra pediatric groups, such as health economists and 
TABLE  1 Key areas for investment in pediatric allergy research
• Prevention of allergic disease(s)
• Better diagnostic tools and evidence-based management
• New drug development and trials, more streamlined, ethical, and 
relevant processes and regulation
• Innovation and technology for better personalized clinical care, 
public health, and research tools. Improved strategic communica-
tion and collaboration with public health, economists, and 
regulatory bodies and the public and press
•	 Fostering	networks	for	research
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appropriately	skilled	 tech	expertise,	will	be	 required	 to	 inform	as-
sessment and trials.
6.5 | Improved strategic communication and 
collaboration
Improved strategic communication and collaboration is related to 
public health, economists, regulatory bodies, the lay public, and the 
press. Pediatric allergists must be strong advocates for their patients.
6.6 | Fostering networks for research
The need for the development of pan- European registries to facilitate 
research and care was highlighted in an EAACI statement by Professor 
Papadopoulos et al. in 2012.9 As an example of the valuable informa-
tion a registry can carry, the European Anaphylaxis Registry has re-
cently provided significant epidemiologic information on the eliciting 
factors of anaphylaxis in children and adolescents.10
At	the	same	time,	a	key	area	for	development	is	the	identification	
of	clinical	centers	involved	or	interested	in	the	care	and	research	work	
in PA. They will represent a platform for research collaboration and 
communication	in	the	form	of	registers	or	clinical	networks.	Currently,	
these	arise	on	an	ad	hoc	basis	for	studies,	but	maintained	networks	
with	 established	 leads	 and	 contact	 points	 are	 likely	 to	 facilitate	 re-
search integration into clinical practice both in the study phase and 
at	 implementation	 of	 new	 guidance.	 A	 drug	 allergy	 network	 exists	
currently.
7  | PLANNING AHEAD
A strategic plan to enhance PA as a specialty should focus on its 
unique	 strengths	and	aim	 to	minimize	 its	weaknesses.	A	 focus	on	
pediatrics and on primary, secondary, and tertiary prevention also 
favors health promotion and cost- effectiveness of EU health sys-
tems. PA requires a defined expertise, while immense research and 
increased	 interest	 are	 taking	place	 in	 this	 field.	 PA,	 as	 a	 pediatric	
subspecialty, has the gratifying ability to intervene early and to im-
prove health and quality of life of allergic children, adolescents, and 
their families, over the long term. Nonetheless, pediatric allergology 
is	 currently	 not	 recognized	 in	 all	 countries,	 and	 there	 is	 a	 lack	 of	
visibility and awareness of the benefits of implementing this sub-
specialty. The wide diversity between nations and the differential 
approach of health implementation priorities will continue to be a 
basis	of	weaknesses	for	PA.
Opportunities are emerging from the rising number of allergic chil-
dren, and PA has the possibility to modulate disease progression and, 
potentially, to provide primary prevention. Allergy at all ages is still 
under- recognized as a health issue by other specialties, as well as by 
government bodies, and this has adverse implications for health and 
research budgets.
Journals publishing on pediatric allergy should inspire and de-
mand quality and timely research by ensuring high acceptance 
standards, critical expert reviews, rapid turnaround times, and elec-
tronic publication.
To	 ensure	 a	 positive	 future	 for	 groundbreaking	 pediatric	 allergy	
research, the roadmap ahead should provide mentorship and support 
for juniors, as well as for established researchers. The appropriate 
signposting of existing support and resources including specific ex-
pertise, mentoring, and research post and funding opportunities is es-
sential. The role and importance of national member organizations are 
the	keys	to	the	grassroots	support	and	growth	of	these	ideas	and	the	
promotion of and for pediatrics in allergy clinical guidance, training, 
research, and policy. EAACI and other Europe- wide or international 
organizations need to provide strategic support to pediatric inclusion 
in these spheres and EAACI already actively support the inclusion of 
meaningful	pediatric	recommendations	in	their	guideline	work.
8  | CONCLUSION
Pediatric allergology as a subspecialty is being better recognized, and a 
universally acceptable standard for training and accreditation is being 
refined. Original research should be promoted, as well as outstanding 
review	articles	for	key	topics.	The	rapid	publication	of	meeting	reports,	
with the aim to provide both an overview and a discussion of the latest 
advances presented in pediatric research would be welcomed.
The role for EAACI and similar organizations worldwide who 
wish to prioritize the agenda for PA needs to include the following: 
broadening of national representation, lobbying for recognition across 
stakeholder	countries,	the	free	movement	of	realistically	funded	spe-
cialists in training, and accurate and well- communicated reports on 
the economic benefits of disease control and prevention for commis-
sioners, policy, and funding bodies. These efforts ultimately have one 
aim—to improve the health and quality of life of children predisposed 
to and suffering with allergic disease.
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